February 24: The Week in Cancer News
Aggressive end-of-life measures are common in people with advanced cancer in nursing homes, and more news selected by the editors of Cancer Today.
Progress Against Cancer
Aggressive end-of-life measures are common in people with advanced cancer in nursing homes, and more news selected by the editors of Cancer Today.
Drugs and mechanical ventilation appear to be effective in preventing potentially fatal damage to cardiovascular muscles, including those in the heart, after immune system is stimulated by immune checkpoint inhibitors. Doctors in France have...
More older women with breast cancer may not need radiation therapy, and more news from the week, selected by the editors of Cancer Today.
Patients with lung cancer who received an immune checkpoint inhibitor before surgery had improved long-term survival rates and lower rates of recurrence than historically observed, according to a study published in an AACR journal....
A drug that selectively targets cancer cells was approved for the treatment of certain HR-positive breast cancers. The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy) for patients with locally advanced...
Patients who receive certain forms of chemo face long-term risk for heart failure, and screening levels for certain cancers remain below expectations.
Guest Post by William G. Nelson, MD, PhD, Editor-in-Chief, Cancer Today Many argue that warfare metaphors, with winners and losers, may not be the best way to imagine the entirety of the cancer experience. With that...
The FDA approved the immune checkpoint inhibitor dostarlimab-gxly to treat advanced uterine cancer with certain mutations. The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) for the treatment of adult patients with...
Immunotherapy before surgery is proving to be an effective treatment against melanoma.
Group says more women should consider removing fallopian tubes to lower ovarian cancer risk, and more stories selected by the editors of Cancer Today.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More